抽象
关于欧洲各地严重哮喘患者的特征和治疗方法,人们知之甚少,但两者可能有所不同。这是欧洲呼吸学会严重异质性哮喘研究协作、以患者为中心(SHAR188bet官网地址P)临床研究协作的第一个研究,旨在探索这些变异。因此,我们的目的是比较欧洲严重哮喘登记和治疗的患者在开始生物治疗前的特点。
这是从加入SHARP既定患者数据库11个国家重度哮喘登记的聚集数据的横截面回顾性分析。
对3236例患者的资料分析显示,在性格特征和生活方式因素方面存在诸多差异。目前吸烟者的比例从0%(波兰和瑞典)到9.5%(比利时)不等,平均体重指数从26.2(意大利)到30.6公斤·米不等-2(the UK) and the largest difference in mean pre-bronchodilator forced expiratory volume in 1 s % predicted was 20.9% (the Netherlands与匈牙利)。Before starting biologicals patients were treated differently between countries: mean inhaled corticosteroid dose ranged from 700 to 1335 µg·day-1来自斯洛文尼亚之间与Poland when starting anti-interleukin (IL)-5 antibody and from 772 to 1344 µg·day-1在那些开始反ige(斯洛文尼亚与西班牙)。在开始使用抗il -5和抗ige的患者中,维持性口服皮质类固醇的使用范围分别为21.0%(比利时)至63.0%(瑞典)和9.1%(丹麦)至56.1%(英国)。
欧洲的严重哮喘的人口都是异构的,在临床特点及治疗不同,经常出现不符合重度哮喘目前欧洲呼吸学会/美国胸科学会指南定义。188bet官网地址治疗方案之前开始生物制品来自于临床试验的入选标准不同,各国之间变化。
抽象
欧洲的重度哮喘人群都是异构的,在临床特点及治疗不同。整个登记和准则协调是必要和需要跨同伙相同数据的收集,以使未来的SHARP研究。http://bit.ly/2krxHPf
脚注
这篇文章有补充资料www.qdcxjkg.com
对SHARP临床研究协作的成员是:B. Abenhardt,实践博士Abenhardt UND约亨Hinrichs先生 - 帕夫利克,德国海德堡;I.M.阿德科克,美国国家心肺研究所,伦敦帝国学院,伦敦,英国;J.阿德勒,欧洲肺脏基金会,英国谢菲尔德;R.阿方索,GSK,达勒姆,NC,USA;R.阿里,巴兹健康NHS信托,英国伦敦;S. Alkameh,Lungenfachpraxis Backnang的,Backnang的,德国;C.阿尔莫纳西德桑切斯,医院拉蒙Ÿ卡哈尔,马德里,西班牙;L.阿尔瓦雷斯,诺华制药公司,瑞士巴塞尔;G.安德森,墨尔本,澳大利亚墨尔本大学,K. Assing,奥尔堡大学医院,奥尔堡,丹麦; S. Ayre, European Lung Foundation, Sheffield, UK; J. Becker, Facharztpraxis für Pneumologie, Lübeck, Germany; E.H.D. Bel, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; K. Bergmann, Charité Berlin Allergie-Centrum, Berlin, Germany; K. Bieksiene, Lithuanian University of Health Science, Kaunas, Lithuania; N. Bjerring, Odense University Hospital, Odense, Denmark; F. Blasi, Milano Respiratory Unit and Adult Cystic Fibrosis Centre and University of Milan, Milan, Italy; P. Bloemen, GSK, Zeist, The Netherlands; H. Blum, MECS Dortmund GmbH, Dortmund, Germany; S. Böing, Pneumoplus, Lungen- und Allergiezentrum, Neuss, Germany; M. Bonavia, Respiratory Rehabilitation, ASL3, Genoa, Italy; A. Bossios, Karolinska University Hospital, Huddinge, Sweden; A. Bourdin, PhyMedExp, INSERM, EFS, Université de Montpellier, CHU Montpellier, Montpellier, France; G-J. Braunstahl, Sint Franciscus Gasthuis and Vlietland, Rotterdam, The Netherlands; A. Brons, European Lung Foundation, Sheffield, UK; G. Brusselle, University of Ghent, UZ Ghent, Ghent; J. Buis, Teva Pharmaceuticals, Amsterdam, The Netherlands; J. Busby, Queen's University Belfast, Belfast, UK; M. Caiaffa, University of Foggia, Foggia, Italy; C. Calabrese, University of Campania “L. Vanvitelli”, Caserta, Italy; G. Camiciottoli, Careggi University Hospital, Florence, Italy; G.W. Canonica, Humanitas University, Rozzano and SANI-Severe Asthma Network Italy, Milan, Italy; H. Cao, Novartis Pharmaceuticals Corp., East Hanover, NJ, USA; C. Caruso, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy; M. Castilla Martínez, Hospital Los Arcos del Mar Menor, Murcia, Spain; S. Centanni, Università degli Studi Milano, Respiratory Unit, ASST Santi Paolo e Carlo, Milan, Italy; K.F. Chung, National Heart and Lung Institute, Imperial College London, London, UK; C. Cisneros Serrano, Hospital de La Princesa, Madrid, Spain; A. Corsico, IRCCS Policlinico San Matteo Foundation and University of Pavia, Pavia, Italy; L. Cosmi, University of Florence, Florence, Italy; M. Costantino, “Carlo Poma” Hospital Mantova, Mantova, Italy; R. Costello, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin, Ireland; N. Crimi, University of Catania, Catania, Italy; Z. Csoma, National Koranyi Institute of Pulmonology, Budapest, Hungary; S. Dahlen, Karolinska Institutet, Stockholm, Sweden; B. Dahlén, Karolinska University Hospital, Huddinge, Sweden; M. D'Amato, “Federico II” University, AO Dei Colli, Naples, Italy; D. Davies, Southampton University Hospital, Southampton, UK; E. Davin, European Lung Foundation, Sheffield, UK; F. de Borja García-Cosío Piqueras, Hospital Son Espases Palma Mallorca, Islas Baleares, Spain; G. Decarlo, European Federation of Allergy and Airways Diseases (EFA), Brussels, Belgium; A. Deimling, Lungenpraxis Schleswig, Schleswig, Germany; S. Del Giacco, University of Cagliari, Cagliari, Italy; R. Diaz Campos, Hospital 12 Octubre, Madrid, Spain; M. Djandji, Medical Affairs, Sanofi Genzyme, Cambridge, MA, USA; R. Djukanovic, University of Southampton, Southampton, UK; D. Doberer, Vienna General Hospital, Vienna, Austria; L. Dupont, University of Leuven, UZ Gasthuisberg Leuven, Leuven, Belgium; K. Dyett, European Lung Foundation, Sheffield, UK; N. Edelbaher, University Clinical Centre Maribor, Maribor, Slovenia; M. Edelmann, Lungenpraxis Aalen, Aalen, Germany; R. Ehmann, Gemeinschaftspraxis für Ambulante Pneumologie mit Allergiezentrum, Stuttgart, Germany; A. Ekberg-Jansson, Dept of Research and Development, Region Halland and University of Gothenburg, Gothenburg, Sweden; A. Farsi, SOS of Allergology and Clinical Immunology, Prato, Azienda USL Toscana Centro, Italy; E. Favero, Vittorio Veneto Hospital, Treviso, Italy; J. Feimer, Pneumologie Odeonsplatz, München, Germany; M. Fletcher, GSK, Brentford, UK; B. Foschino, University of Foggia, Foggia, Italy; B. Frankemölle, European Lung Foundation, Sheffield, UK; M. Gaga, Athens Chest Hospital Sotiria, Athens, Greece; M. Gappa, Marien-Hospital, Klinik für Kinder- und Jugendmedizin, Wesel, Germany; J. García de Pedro, Hospital Gregorio, Marañón, Madrid, Spain; J. García Rivero, Hospital Laredo, Laredo, Spain; M. Gasplmayr, Kardiologische und Fachinternistische ÜBAG Dr Sandrock und Partner, Altdorf bei Nürnberg, Germany; R. Gebhardt, Facharzt für Lungen- und Brochialheilkunde, Allergologie und Umweltmedizin, Berlin, Germany; H. Geldmacher, Pneumologicum, Hannover, Germany; C. Geltner, Kreisklinik Bad Reichenhall, Bad Reichenhall, Germany; M. Gerstlauer, Klinikum Augsburg, II Kinderklinik, Augsburg, Germany; T. Gibson, European Lung Foundation, Sheffield, UK; G. Giuseppe, AO S. Croce e Carle, Cuneo, Italy; C. Gogoll, Evangelische Elisabeth Klinik, Berlin, Germany; V. Grimm-Sachs, Praxis Dr Grimm-Sachs, Bruchsal, Germany; I. Grisle, Riga Eastern Clinical University Hospital, Riga, Latvia; B. Grün, Praxis Dr Grün, Bad Windsheim, Germany; A. Grünewaldt, Universitätsklinikum Frankfurt, Frankfurt, Germany; G. Guarnieri, University of Padua, Padova, Italy; J. Gullón Blanco, Hospital San Agustín, Avilés, Asturias, Spain; E. Hamelmann, Klinik für Kinder- und Jugendmedizin Kinderzentrum Bethel, Bielefeld, Germany; D. Hamerlijnck, European Lung Foundation, Sheffield, UK; A. Hammers-Reinhard, Praxis Hammers-Reinhard, Homburg-Saar, Germany; S. Hanon, Free University Brussel, Academic Ziekenhuis, Jette, Belgium; S. Hansen, Bispebjerg University Hospital, Copenhagen, Denmark; D. Harzheim, Waldburg-Zeil Kliniken – Fachkliniken Wangen, Wangen im Allgäu, Germany; L. Heaney, Queens University Belfast and Belfast Health and Social Care Trust, Belfast, UK; E. Heffler, Humanitas University, Rozzano and SANI-Severe Asthma Network Italy, Milan, Italy; S. Hellmich, Pneumologie am Schelztor Esslingen, Esslingen, Germany; M. Herden, Lungenfachärztlich-Internistische Schwerpunktpraxis, Freising, Germany; T. Hering, Arzt für Pneumologie, Allergologie, Schlafmedizin, Berlin, Germany; F. Herth, Thoraxklinik Heidelberg gGmbH, Heidelberg, Germany; O. Hilberg, Vejle Hospital, Vejle, Denmark; I. Horvath, National Koranyi Institute of Pulmonology, Budapest, Hungary; P. Howarth, GSK, Brentford, UK; M. Hubatsch, Lungenarztpraxis Dr Hubatsch, Heilbronn, Germany; M. Humbert, Université Paris-Sud, Le Kremlin-Bicêtre, France; K. Husemann, MVZ Klinikum Kempten, Praxis für Pneumologie und Allergologie, Kempten, Germany; M. Idzko, Klinik für Pneumologie, Universitätsklinikum Freiburg, Freiburg, Germany; D. Jackson, Guy's and St Thomas' NHS Trust and King's College London, London, UK; M. Jandl, Hamburger Institut für Therapieforschung GmbH, Hamburg, Germany; X. Jaumont, Novartis Pharma AG, Basel, Switzerland; G. Joos, UZ Gent, University of Gent, Belgium; M. Jöst, Malteser Lungen- und Allergiezentrum Bonn, Bonn, Germany; M. Jüch, Pneumologische Praxis am Ulrichplatz, Magdeburg, Germany; M. Kabesch, Krankenhaus Barmherzige Brüder Regensburg, Regensburg, Germany; P. Kaiser-Labusch, Klinikum Bremen Mitte, Bremen, Germany; P. Kardos, Studienzentrum Maingau, Frankfurt, Germany; F. Käßner, MECS Cottbus, Cottbus, Germany; T. Keeley, GSK, Brentford, UK; W. Kerr, GSK, Brentford, UK; J. Kirschner, CIMS Studienzentrum Bamberg, GmbH, Bamberg, Germany; L. Klimek, Zentrum für Rhinologie und Allergologie, Wiesbaden, Germany; M. Koca, Lungenpraxis Offenbach, Offenbach, Germany; R. Koczulla, Schönklinik Berchtesgadener Land, Schönau am Königsee, Germany; C. Koerner-Rettberg, Klinik für Kinder- und Jugendmedizin der RUB im St Josef-Hospital, Bochum, Germany; P. Kopac, University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia; S. Korn, Universitätsmedizin Mainz, Mainz, Germany; S. Korn, Schwerpunkt Pneumologie, Universitätsmedizin Mainz, Mainz, Germany; M. Kots, Chiesi Farmaceutici, Parma, Italy; J. Kronsbein, Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil, Bochum, Germany; P. Kuna, Medical University of Lodz, Lodz, Poland; I. Kupryś Lipinska, Medical University of Lodz, Poland; N. Kwon, GSK, Brentford, UK; M. Langer, Lungenpraxis Dr Langer Tübingen, Tübingen, Germany; B. Langeveld, Deventer Hospital, Deventer, The Netherlands; A. Lantz, Karolinska University Hospital, Huddinge, Sweden; N. Lazarinis, Karolinska University Hospital, Huddinge, Sweden; Z. Lazic, University Clinical Centre Kragujevac, Kragujevac, Serbia; L. Lehtimäki, University of Tampere, Tampere, Finland; J. Leuppi, University Clinic of Internal Medicine, Basel, Switzerland; C. Lombardi, Hospital Institute Fondazione Poliambulanza, Brescia, Italy; M. Lommatzsch, Universität Rostock, Abteilung Pneumologie, Rostock, Germany; A. López-Viña, Hospital Puerta Hierro, Majadahonda, Madrid, Spain; R. Louis, CHU Liege, GIGA-I3 Research Group, University of Liege, Liege, Belgium; R. Luca, Catholic University of the Sacred Heart, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy; D. Lúðvíksdóttir, Landspitali University Hospital, Reykjavik, Iceland; C. Lüttecke-Hecht, Lungenfacharztpraxis Dr C. Lüttecke-Hecht, Mainz, Germany; L. Macchia, University of Bari – Aldo Moro, Bari, Italy; T. Magni, Chiesi Farmaceutici, Parma, Italy; A.H. Maitland-van der Zee, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; C. Martínez Rivera, Hospital Germans Trias i Pujol, Badalona, Barcelona; P. Mastoridis, Novartis Pharmaceuticals Corp., East Hanover, NJ, USA; F. Mazza, Presidio Ospedaliero of Pordenone, Pordenone, Italy; F. Menzella, Santa Maria Nuova Hospital, Azienda USL di Reggio Emilia IRCCS, Reggio Emilia, Italy; A. Menzies-Gow, Royal Brompton Hospital and Imperial College London, London, UK; A. Michils, Hôpital Erasme, Bruxelles, Belgium; F. Mihălţan, University of Medicine and Pharmacy “Carol Davila”, Bucharest, Romania; M. Milanese, Pulmonology Unit, ASL2 Savonese, Pietra Ligure, Savona, Italy; K. Milger-Kneidinger, Klinikum der Universität München, München, Germany; J. Molinska, Medical University of Lodz, Lodz, Poland; I. Montagna, Chiesi Farmaceutici, Parma, Italy; P. Montuschi, Catholic University of the Sacred Heart, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy; N. Mülleneisen, Asthma und Allergiezentrum, Leverskusen, Germany; M. Muñoz Esquerre, Hospital Bellvitge, Barcelona, Spain; A. Nanzer-Kelly, Guy's and St Thomas' NHS Trust and King's College London, London, UK; N. Nenasheva, Russian Medical Academy for Postgraduate Education, Moscow, Russia; C. Neurohr, Klinik Schillerhöhe, Abteilung für Pneumologie und Beatmungsmedizin, Gerlingen, Germany; E. Nucera, Catholic University of the Sacred Heart, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy; J. Otker, European Lung Foundation, Sheffield, UK; K. Oud, Hospital Gelderse Vallei, Ede, The Netherlands; P. Paggiaro, University of Pisa, Pisa, Italy; R. Parente, University of Salerno, Salerno, Italy; J. Parkinson, Asthma UK, London, UK; G. Passalacqua, IRCCS Policlinico San Martino, University of Genoa, Genoa, Italy; N. Patberg, Isala Hospital, Zwolle, The Netherlands; V. Patella, “Santa Maria della Speranza” Hospital, Battipaglia, Salerno, Italy; O. Patino, Teva Pharmaceuticals, Amsterdam, The Netherlands; T. Paulsson, GSK, Brentford, UK; R. Peche, Hôpital Vésale, Charleroi, France; G. Pelaia, University Magna Graecia of Catanzaro, Catanzaro, Italy; E. Peress, Novartis Pharma AG, Basel, Switzerland; L. Pérez de Llano, Hospital Lucus Augusti, Lugo, Spain; P. Pfeffer, Barts Health NHS Trust and Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK; P. Pfister, Novartis Pharma AG, Basel, Switzerland; C. Pilette, CHU Saint Luc, Université Catholique de Louvain, Belgium; C. Pinedo Sierra, Hospital San Carlos, Madrid, Spain; L. Pini, University of Brescia, Spedali Civili di Brescia, Brescia, Italy; V. Plaza, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; C. Porsbjerg, Bispebjerg University Hospital, Copenhagen, Denmark; F. Powitz, Pneumologie Elisenhof München, München, Germany; D. Ramos-Barbon, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; T. Ranger, European Lung Foundation, Sheffield, UK; L. Rasmussen, Copenhagen University Hospital Gentofte, Gentofte, Denmark; K. Rasmussen, Zealand University Hospital, Roskilde, Denmark; M. Rezelj, University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia; L. Ricciardi, University Hospital “G. Martino”, University of Messina, Italy; F. Ricciardolo, University of Torino, San Luigi Hospital, Orbassano, Torino, Italy; L.B. Richards, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; E. Ridolo, University of Parma, Parma, Italy; L. Rijssenbeek-Nouwens, Dutch Asthma Centre Davos, Davos, Switzerland; G. Rolla, AO Mauriziano Hospital, University of Torino, Turin, Italy; D. Romero Ribate, Hospital La Paz, Madrid, Spain; S. Rüdiger, Universitätsklinikum Ulm, Ulm, Germany; G. Safioti, Teva Pharmaceuticals, Amsterdam, The Netherlands; T. Sandström, Umeå University, Umeå, Sweden; P. Santus, Università degli Studi di Milano, Sacco University Hospital, ASST Fatebenefratelli-Sacco, Milano, Italy; R. Sauer, Lungenzentrum Ulm, Ulm, Germany; G. Schauerte, CJD Berchtesgaden, Asthmazentrum und Diabeteszentrum, Berchtesgaden, Germany; R. Schipmann, Klinik Martinusquelle, Bad Lippspringe, Germany; F. Schleich, University of Liege, CHU Liege, Liege, Belgium; J. Schmid, Aarhus University Hospital, Aarhus, Denmark; F. Schmidt, Pneumologische Gemeinschaftspraxis Dr Schmidt und Weeg, München, Germany; O. Schmidt, Lungenfachärzte KSS, Koblenz, Germany; M. Schmitz, Pneumo Westpfalz, Kaiserslautern, Germany; T. Schrag, Praxis Dr med. Till Schrag, Bad Reichenhall, Germany; S. Schröer, Internistische Schwerpunktpraxis, Villingen-Schwenningen, Germany; K. Schultz, Klinik Bad Reichenhall, Bad Reichenhall, Germany; C. Schulz, Universitätsklinikum Regensburg, Regensburg, Germany; N. Scichilone, University of Palermo, Palermo, Italy; V. Sedlak, Czech Pneumology and Phthiseology Society, Prague, Czech Republic; J. Selb, University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia; G. Senna, University Hospital of Verona, Verona, Italy; S. Sergejeva, University of Tartu, Tartu, Estonia; J. Serrano Pariente, Hospital Inca, Islas Baleares, Spain; M. Sichau, MVZ für Diagnostik und Therapie, Herne, Germany; D. Simona, AV3 ASUR Marche, Hospital Civitanova Marche, Macerata, Italy; A. Singer, Barts Health NHS Trust, London UK; D. Skowasch, Universitätsklinikum Bonn, Bonn, Germany; S. Škrgat, University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia; F. Smeenk, Catharina Hospital, Eindhoven, The Netherlands; S. Smith, GSK, Durham, NC, USA; P. Solidoro, University of Turin, Turin, Italy; J.K. Sont, Leiden University Medical Centre, Leiden, The Netherlands; G. Spadaro, AO Universitaria Federico II, Naples, Italy; A. Spanevello, Istituti Clinici Scientifici Maugeri IRCCS, Tradate, Italy and University of Insubria, Varese, Italy; M. Stefansdottir, European Lung Foundation, Sheffield, UK; K. Steinmetz, Gemeinschaftspraxis, Darmstadt, Germany; J. Steiß, Universitätsklinikum Giessen, Giessen, Germany; M. Stephan, Klinik Löwenstein, Löwenstein, Germany; S. Stieglitz, Wuppertaler Lungenzentrum, Wuppertal, Germany; H. Suhling, MH Hannover, Hannover, Germany; C. Taube, Universitätsmedizin Essen, Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH, Essen, Germany; A. ten Brinke, Medical Centre Leeuwarden, Leeuwarden, The Netherlands; S. Tolga Yavuz, Universitätsklinikum Bonn, Bonn, Germany; N. Tudoric, Dubrava University Hospital, Zagreb, Croatia; C. Ulrik, Hvidovre University Hospital, Copenhagen, Denmark; J.J.M.H. van Bragt, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; M. van de Ven, Rijnstate Hospital, Arnhem, The Netherlands; F. van den Elshout, Rijnstate Hospital, Arnhem, The Netherlands; M. Van Dyke, GSK,Collegeville, PA, USA; S. van Nederveen-Bendien, Haga Hospital, The Hague, The Netherlands; I. van Veen, Medisch Spectrum Twente, Enschede, The Netherlands; O. Vandenplas, CHU Godine Namur, Belgium; K. Velthove, GSK, Zeist, The Netherlands; A. Vianello, University of Padova, Padova, Italy; S.J.H. Vijverberg, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; C. Vogelberg, Universitätsklinikum Carl Gustav Carus, Klinik und Poliklinik für Kinder- und Jugendmedizin, Dresden, Germany; S.S. Wagers, BioSciConsulting, Maasmechelen, Belgium; E. Wallén-Nielsen, Karolinska University Hospital, Huddinge, Sweden; E.J. Weersink, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; T. Wisskirchen, Aeroprax, Wuppertal, Germany; M. Yacoub, San Raffaele Hospital of Milano, Milan, Italy; S. Yancey, GSK, Durham, NC, USA; V. Yasinska, Karolinska University Hospital, Huddinge, Sweden; M. Zappa, Sandro Pertini Hospital, Rome, Italy; S. Zielen, Universitätsklinikum Frankfurt, Frankfurt, Germany; C. Zimmermann, Pneumologische Praxis Reutlingen, Reutlingen, Germany; R. Zimmermann, Klinikum Landshut, Medizinische Klinik 2, Landshut, Germany.
利益冲突:J.J.M.H. van Bragt没有什么要披露的。
利益冲突:I.M. Adcock没有什么要披露的。
利益冲突:E.H.D. Bel报告了来自阿斯利康、葛兰素史克和诺华的资助和个人费用,来自Teva的资助,以及来自Boehringer Ingelheim、赛诺菲/Regeneron、Vectura和Sterna的个人费用。
利益冲突:G-J。Braunstahl报告了来自葛兰素史克、诺华、阿斯利康和基耶西的资助,这些资助都在提交的作品之外。
利益冲突:A.十Brinke报告制度费用由GSK,Teva公司和阿斯利康,从赛诺菲,诺华公司和勃林格殷格翰,外面提交作品研究咨询委员会事业性收费的研究顾问委员会和讲座。
利益冲突:J.巴斯比有没有透露。
利益冲突:G.W.卡诺尼卡研究进行期间报告的个人费用从A Menarini,阿斯利康,勃林格殷格翰,基耶西FARMACEUTICI,Circassia,GSK,MSD,诺华,罗氏,赛诺菲 - 安万特公司和Teva公司。
利益冲突:H.曹是诺华,这是夏普的资金制药公司之一的员工。
利益冲突:K.F.钟已收到酬金参与由葛兰素史克,阿斯利康,诺华,默克公司,勃林格殷格翰公司和Teva公司就用于治疗哮喘和慢性阻塞性肺病和也已报酬的演讲治疗顾问委员会会议。
利益冲突:Z. Csoma有没有透露。
利益冲突:B.Dahlén报道了Teva公司,葛兰素史克和赛诺菲,从阿斯利康讲座,提交作品之外的个人费用顾问董事会成员。
利益冲突:E.达文有没有透露。
利益冲突:S.汉森没有透露。
利益冲突:E. Heffler报告了来自阿斯利康(AstraZeneca)、赛诺菲(Sanofi Genzyme)、梯瓦(Teva)、诺华(Novartis)、葛兰素史克(GSK)、西卡西亚(Circassia)和雀巢(Nestle)的个人费用。
利益冲突:一,霍瓦特阿斯利康,勃林格殷格翰,葛兰素史克,基耶西,柏林化学公司,罗氏,MSD,CSL和萨格尔制药,外提交的工作报告个人费用。
利益冲突:S.科恩的研究进行期间报告从ALMIRALL,阿斯利康,勃林格殷格翰,基耶西,Teva公司和罗氏,赠款和葛兰素史克和诺华公司,个人收费的个人费用。
利益冲突:M. Kots是一个全职基耶西Famaceutici SpA公司员工,全球临床开发部门。
利益冲突:P.库纳的报告讲座,由阿斯利康和诺华公司,讲学和从柏林化学公司,Menarini和勃林格殷格翰会议签到,提交作品外非金融支持个人费用咨询委员会工作的个人费用。
利益冲突:N.权是GSK的员工。
R.路易报告补助和个人费用从葛兰素史克,阿斯利康和诺华,从基耶西助学金,提交作品外顾问委员会的工作:利益冲突。
五,广场的报道补助,个人收费和非金融支持基耶西,赠款和阿斯利康的个人费用,由ALK,Mundipharma和赛诺菲,从Menarini补助费的个人,提交作品外:利益冲突。
利益冲突:C. Porsbjerg有没有透露。
利益冲突:D. Ramos-Barbon没有要披露的内容。
利益冲突:L.B.理查兹有没有透露。
利益冲突:美国Škrgat报告个人费用讲座和科学讨论座谈会Teva和勃林格,个人费用从阿斯利康讲座和咨询委员会,葛兰素史克,Berlin-Chemie和基耶西,在提交工作。
利益冲突:J.K. Sont没有什么要披露的。
利益冲突:S.J.H. Vijverberg没有什么要披露的。
利益冲突:E.J。Weersink有没有透露。
利益冲突:五Yasinska有没有透露。
利益冲突:S.S. Wagers报告了来自欧洲呼吸协会(European Respiratory Society)在研究期间的咨询费;188bet官网地址咨询费用从国王学院医院NHS信托基金会,学术医学研究,AMC医学研究BV英国哮喘,雅典医学院,勃林格殷格翰集团国际GmbH,楚de图卢兹,西罗,DS生物制品有限公司,洛桑联邦理工欧洲呼吸学会FISEVI,射流分析,游戏内弗劳恩霍夫,弗劳恩霍夫项目,葛兰素史克研发有限公司、荷兰和骑士,卡罗林斯卡医学院Fakturor, KU鲁汶Longfonds,国家心肺研究所,188bet官网地址诺华制药公司Owlstone医疗有限公司,PExA AB,联合生物制药SPRL,联合生物科学GmbH是一家现代化的、于默奥大学,南安普顿大学医院NHS信托基金会,意大利校园Bio-Medico di罗马,意大利Cattolica Del Sacro库雷,乌尔姆大学,伯尔尼大学,爱丁堡大学,赫尔大学,莱斯特大学,拉夫堡大学,卢森堡大学,曼彻斯特大学,诺丁汉大学,弗兰芒布拉班特省,Dienst欧罗巴,伦敦帝国理工学院,勃林格殷格翰,艾索麦,Gossamer Bio,阿斯利康和CIBER,在提交作品之外。
利益冲突:R.久卡诺维奇报告接受费在诺华,阿斯利康和梯瓦公司,梯瓦为诺华公司作为咨询顾问委员会委员,并在有关组织的葛兰素史克哮喘科学讨论参与组织了专题讨论会演讲;并且是共同创始人和现任顾问,并在Synairgen,南安普敦大学的旋出公司拥有的股份。
利益冲突:梅特兰回历,范德Zee的报告个人费用参与阿斯利康和勃林格殷格翰,由勃林格殷格翰公司和葛兰素史克无限制研究基金的顾问委员会。
- 收到了2019年6月14日。
- 公认2019年9月18日。
- 版权©2020人队
个人
登录使用您的用户名和密码
图书馆用户
通过您的机构登录
购买访问
联系我们
如果您对ERS出版物网站有任何问题,请联系我们journals@ersnet.org